Premium
Efficacy and safety of a novel water‐soluble herbal patch for acne vulgaris treatment: A randomized, assessor‐blinds controlled, intra‐individual split‐face comparative study
Author(s) -
Jaturapisanukul Kulwipapat,
Udompataikul Montree,
Kanokrungsee Silada,
Rojhirunsakool Salinee,
Kamanamool Nanticha,
Rachpirom Mingkwan,
Puttarak Panupong
Publication year - 2021
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14925
Subject(s) - medicine , acne , erythema , dermatology , randomized controlled trial , adverse effect , antibiotics , erythromycin , significant difference , microbiology and biotechnology , biology
Acne vulgaris is a chronic inflammatory skin disease. Antibiotics, particularly clindamycin and erythromycin, are used for the treatment of acne vulgaris. However, emerging antibiotic‐resistant strains have been an important problem. This study aims to evaluate the efficiency and safety of a novel water‐soluble herbal acne patch (WHAP) compared with the hydrocolloid acne patch (HAP) in mild to moderate inflammatory acne patients. The randomized, assessor‐blind controlled, intra‐individual split‐face study was performed on 49 acne patients. The clinical outcomes were evaluated on day 2, 4, 7, 9, and 11 of treatment. It was shown that the median time to resolution of the inflammatory acne treated with WHAP was shorter than HAP with a statistically significant difference (WHAP was 4 days, whereas HAP was 6 days) ( P value <.001). Moreover, WHAP had a more significant decrease in the rate of inflammatory diameter, erythema scores (by clinical and colorimetry), and a more increase in the rate of lightness scores (by colorimetry) than HAP ( P value <.05). No adverse effects were reported in both groups. It is safe to use WHAP as an alternative treatment for inflammatory acne.